Several studies have shown that suppressing the production of NETs by inhibiting the functions of PAD4 and/or GSDMD provides therapeutic or protective effects in autoimmune diseases (12, 13), suggesting that PAD4 and GSDMD can serve as potential therapeutic targets (11, 14). The gene discussed is GSDMD; the disease is autoimmune disease.